LEXX a penny medical stock LONGLEXX on the daily chart is on a big bullrun breaking out of an ascending broadening triangle
or megaphone pattern demostrative of increasing volatility. Retlative volumes are 2X the
historical comparison. Price is now on the approach to the highs of 2023 but is only 15% of
the all high highs
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.58 USD
−5.80 M USD
464.28 K USD
16.28 M
About Lexaria Bioscience Corp.
Sector
Industry
CEO
Richard C. Christopher
Website
Headquarters
Kelowna
Founded
2004
FIGI
BBG000JQHT18
Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. It operates through the following segments: IP Licensing, B2B Product, Research and Development, and Corporate. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.
LONG SIGNAL LEXX STOCKThe next challenge is to find the right exit point. Of course, this must be above the purchase and additional costs, i.e. possible commissions and spreads. To minimize the risk, it's better to get out sooner than too late. Here too, it is important to use technical analysis to identify the reversal
$LLEX entry PT 6.30-7-8 Target PTs 15 and higher Long term PT 60$LLEX entry PT 6.30-7-8 Target PTs 15 and higher Long term PT 60
BULLISH CYPHER PATTERN
Spike in Volume
Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ing
Lexaria Provides Guidance on Upcoming R&DLexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering
Lexaria also announced the pricing of an underwritten public offering (the "Offering") of 1,828,571 units, each unit consisting of one share of common stock and one warrant to p
LEXX -- Biotech play trading below just closed $5.25 financing$13.2M mkt cap, 3.5M float. Freshly uplisted to NASDAQ. Closed $11M oversubscribed financing at $5.25 on January 14th and trading at discount at $4.40. Oversold on the daily (RSI @ 28). Accum/Dist is evening out after 3 days of selloff. Gap at 6.41. Cash + assets exceed current market cap.
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of LEXX is 1.38 USD — it has decreased by −2.10% in the past 24 hours. Watch Lexaria Bioscience Corp. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Lexaria Bioscience Corp. stocks are traded under the ticker LEXX.
LEXX stock has risen by 3.70% compared to the previous week, the month change is a 2.19% rise, over the last year Lexaria Bioscience Corp. has showed a −40.00% decrease.
We've gathered analysts' opinions on Lexaria Bioscience Corp. future price: according to them, LEXX price has a max estimate of 8.00 USD and a min estimate of 6.00 USD. Watch LEXX chart and read a more detailed Lexaria Bioscience Corp. stock forecast: see what analysts think of Lexaria Bioscience Corp. and suggest that you do with its stocks.
LEXX reached its all-time high on Oct 12, 2007 with the price of 180.00 USD, and its all-time low was 0.22 USD and was reached on Nov 21, 2012. View more price dynamics on LEXX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
LEXX stock is 10.41% volatile and has beta coefficient of 0.95. Track Lexaria Bioscience Corp. stock price on the chart and check out the list of the most volatile stocks — is Lexaria Bioscience Corp. there?
Today Lexaria Bioscience Corp. has the market capitalization of 24.58 M, it has increased by 2.18% over the last week.
Yes, you can track Lexaria Bioscience Corp. financials in yearly and quarterly reports right on TradingView.
Lexaria Bioscience Corp. is going to release the next earnings report on Jul 18, 2025. Keep track of upcoming events with our Earnings Calendar.
LEXX net income for the last quarter is −2.71 M USD, while the quarter before that showed −2.70 M USD of net income which accounts for −0.35% change. Track more Lexaria Bioscience Corp. financial stats to get the full picture.
No, LEXX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 18, 2025, the company has 7 employees. See our rating of the largest employees — is Lexaria Bioscience Corp. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Lexaria Bioscience Corp. EBITDA is −9.20 M USD, and current EBITDA margin is −1.21 K%. See more stats in Lexaria Bioscience Corp. financial statements.
Like other stocks, LEXX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Lexaria Bioscience Corp. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Lexaria Bioscience Corp. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Lexaria Bioscience Corp. stock shows the sell signal. See more of Lexaria Bioscience Corp. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.